| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
(20R)-Ginsenoside Rh1 targets multiple pathways. It inhibits the thrombin-induced conversion of fibrinogen to fibrin, indicating an antithrombotic effect. It shows neurotrophic activity in rat PC12 cells by stimulating NGF-induced neurite outgrowth. It modulates key signaling pathways such as NF-κB, MAPK, and PI3K/Akt, contributing to its anti-inflammatory, antioxidant, and neuroprotective effects. The stereochemistry plays a role in its activity, with 20(S)-Rh1 showing stronger anti-inflammatory activity than 20(R)-Rh1 in BV-2 microglia.
|
|---|---|
| ln Vitro |
In vitro, (20R)-Ginsenoside Rh1 inhibits the thrombin-induced conversion of fibrinogen to fibrin. It shows neurotrophic activity in rat PC12 cells by stimulating NGF-induced neurite outgrowth, exhibiting 8.5% activity at a 10 µM concentration after 72 hours. It also exhibits anti-inflammatory, antioxidant, and anticancer effects in various cell models. Its activity is dependent on the stereochemistry, with 20(S)-Rh1 showing stronger anti-inflammatory activity than 20(R)-Rh1.
|
| ln Vivo |
In vivo activity data for (20R)-Ginsenoside Rh1 is limited in publicly available literature. As a compound with potent anti-inflammatory, antioxidant, neuroprotective, and anticancer effects in vitro, it is hypothesized to exhibit similar effects in animal models. However, specific in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, have not been detailed in the available sources. Further research is needed to fully characterize its in vivo activity and therapeutic potential.
|
| Enzyme Assay |
For cell-free enzyme assays, the antithrombotic activity of (20R)-Ginsenoside Rh1 can be assessed by measuring its inhibition of thrombin activity. This can be done using a chromogenic substrate specific for thrombin. Varying concentrations of the compound are incubated with thrombin and the substrate, and the rate of substrate cleavage is measured spectrophotometrically. The IC50 for thrombin inhibition can be calculated. Its neurotrophic activity can be studied in cell-free systems by measuring its effect on NGF-induced TrkA receptor phosphorylation.
|
| Cell Assay |
For in vitro cellular assays, the neurotrophic activity of (20R)-Ginsenoside Rh1 is assessed in rat PC12 cells. Cells are treated with NGF and varying concentrations of the compound. After 72 hours, neurite outgrowth is quantified by microscopy. The percentage of cells with neurites and the length of neurites are measured. Its anti-inflammatory activity can be assessed in LPS-stimulated BV-2 microglia cells by measuring the production of inflammatory cytokines.
|
| Animal Protocol |
For in vivo studies, (20R)-Ginsenoside Rh1 could be administered orally or intraperitoneally in rodent models of thrombosis, inflammation, or neurodegenerative diseases. In a model of thrombosis, its antithrombotic effect could be assessed by measuring the time to occlusion in a carotid artery injury model. In a model of neuroinflammation, its anti-inflammatory effect could be assessed by measuring microglial activation and cytokine levels in the brain.
|
| ADME/Pharmacokinetics |
(20R)-Ginsenoside Rh1 has a molecular formula of C36H62O9 and a molecular weight of 638.87 g/mol. Its CAS number is 80952-71-2. It is typically supplied as a powder. It is soluble in DMSO and ethanol. For in vitro studies, stock solutions are prepared in DMSO. For in vivo administration, it can be formulated in suitable vehicles. Storage is recommended at -20°C for up to 3 years. Its purity is typically >98% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural ginsenoside, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that the observed effects are not due to a general reduction in cell viability.
|
| References | |
| Additional Infomation |
According to reports, 2-[[3,12-dihydroxy-17-(2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecylhydro-1H-cyclopenta[a]phenanthrene-6-yl]oxy]-6-(hydroxymethyl)oxacyclohexane-3,4,5-triol has been found in Gynostemma pentaphyllum, ginseng, and other organisms with available data.
(20R)-Ginsenoside Rh1 is a research-grade compound and is not approved for any therapeutic use. It serves primarily as a valuable pharmacological tool for studying the mechanisms of ginsenosides. Its mechanism of action involves the modulation of NF-κB, MAPK, and PI3K/Akt pathways, as well as the inhibition of thrombin activity. Its neurotrophic and anti-inflammatory activities make it a compound of interest for drug discovery. No clinical trials have been reported. |
| Molecular Formula |
C36H62O9
|
|---|---|
| Molecular Weight |
638.8721
|
| Exact Mass |
638.439
|
| CAS # |
80952-71-2
|
| Related CAS # |
Ginsenoside Rh1;63223-86-9
|
| PubChem CID |
12855917
|
| Appearance |
White to off-white solid powder
|
| Density |
1.23±0.1 g/cm3
|
| Boiling Point |
755.1±60.0 °C at 760 mmHg
|
| Flash Point |
410.5±32.9 °C
|
| Vapour Pressure |
0.0±5.7 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
3.74
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
45
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RAQNTCRNSXYLAH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C36H62O9/c1-19(2)10-9-13-36(8,43)20-11-15-34(6)26(20)21(38)16-24-33(5)14-12-25(39)32(3,4)30(33)22(17-35(24,34)7)44-31-29(42)28(41)27(40)23(18-37)45-31/h10,20-31,37-43H,9,11-18H2,1-8H3
|
| Chemical Name |
2-[[3,12-dihydroxy-17-(2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~156.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 10 mg/mL (15.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 10 mg/mL (15.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 10 mg/mL (15.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5653 mL | 7.8263 mL | 15.6526 mL | |
| 5 mM | 0.3131 mL | 1.5653 mL | 3.1305 mL | |
| 10 mM | 0.1565 mL | 0.7826 mL | 1.5653 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
